Carcinoid heart disease

Alain M. Bernheim, Heidi M. Connolly, Pellikka Patricia

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


In patients with carcinoid heart disease, a multidisciplinary approach to patient are is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90% of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.

Original languageEnglish (US)
Pages (from-to)482-489
Number of pages8
JournalCurrent Treatment Options in Cardiovascular Medicine
Issue number6
StatePublished - Dec 2007

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Carcinoid heart disease'. Together they form a unique fingerprint.

Cite this